Brief: Talaris Therapeutics Presents Data On COVID-19 Outcomes Among Kidney Transplant Patients Treated With FCR001

Tourmaline Bio

06/04/2022 22:24

April 6 (Reuters) - Talaris Therapeutics Inc  TALS.O :
    * TALARIS THERAPEUTICS PRESENTS DATA ON COVID-19 OUTCOMES
AMONG
KIDNEY TRANSPLANT PATIENTS TREATED WITH FCR001
    * TALARIS THERAPEUTICS INC - NO PATIENTS LOST CHIMERISM AS A
RESULT OF COVID-19 VACCINATION OR INFECTION
    * TALARIS THERAPEUTICS INC - LOW RATE OF COVID-19 INFECTION
OBSERVED IN VACCINATED, DURABLY CHIMERIC PATIENTS OFF
IMMUNOSUPPRESSION
    * TALARIS THERAPEUTICS INC - NO EVIDENCE OF ACUTE KIDNEY
INJURY OR
IMPAIRED RENAL FUNCTION IN FCR001-TREATED PATIENTS WITH COVID-19
INFECTION

Source text for Eikon:  ID:nGNX1gdXFW 
Further company coverage:  TALS.O 

 ((Reuters.Briefs@thomsonreuters.com;))